teleo-codex/domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

type	domain	description	confidence	source	created	title	agent	scope	sourcer	related_claims	supports	reweave_edges
claim	health	The healthcare system systematically denies access to the populations with the highest disease burden through the combination of state Medicaid policy and income distribution	likely	KFF + Health Management Academy, 2025-2026 Medicaid coverage and spending analysis	2026-04-13	GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs	vida	structural	KFF + Health Management Academy	GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm	Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients	Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14 Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14

GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs

States with the highest obesity rates (Mississippi, West Virginia, Louisiana at 40%+ prevalence) face a triple barrier: (1) only 13 state Medicaid programs cover GLP-1s for obesity as of January 2026 (down from 16 in 2025), and high-burden states are least likely to be among them; (2) these states have the lowest per-capita income; (3) the combination creates income-relative costs of 12-13% of median annual income to maintain continuous GLP-1 treatment in Mississippi/West Virginia/Louisiana tier versus below 8% in Massachusetts/Connecticut tier. Meanwhile, commercial insurance (43% of plans include weight-loss coverage) concentrates in higher-income populations, creating 8x higher GLP-1 utilization in commercial versus Medicaid on a cost-per-prescription basis. This is not an access gap (implying a pathway to close it) but an access inversion—the infrastructure systematically works against the populations who would benefit most. Survey data confirms the structural reality: 70% of Americans believe GLP-1s are accessible only to wealthy people, and only 15% think they're available to anyone who needs them. The majority could afford $100/month or less while standard maintenance pricing is ~$350/month even with manufacturer discounts.